Get started
Author

Alessia Cavo

Observed names: A Cavo, A. Cavo, Cavo A, Cavo A., Cavo, Alessia
ORCID: 0000-0003-2157-3740
Observed ORCID: 0000-0003-2157-3740
OpenAlex ID: A5077883336
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)
2021 · Sara Elena Rebuzzi, Alessio Signori, et al. · Therapeutic Advances in Medical Oncology · 107
PDF
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial
2023 · A.O. Siefker-Radtke, N. Matsubara, et al. · Annals of Oncology · 96
PDF
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors
2024 · Brigida Anna Maiorano, Massimo Di Maio, et al. · JAMA Network Open · 55
Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers
2020 · Lucia Nappi, Margaret Ottaviano, et al. · The Oncologist · 38
PDF
Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223
2019 · Matteo Bauckneht, Selene Capitanio, et al. · Cancers · 38
PDF
Effectiveness and Safety of Immune Checkpoint Inhibitors for Patients with Advanced Non Small-Cell Lung Cancer in Real-World: Review and Meta-Analysis
2021 · Manlio Mencoboni, Marcello Ceppi, et al. · Cancers · 37
PDF
Targeting androgen-independent pathways: new chances for patients with prostate cancer?
2017 · C. Cattrini, E. Zanardi, et al. · Critical Reviews in Oncology/Hematology · 30
PDF
Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer
2020 · Orazio Caffo, Donatello Gasparro, et al. · European Journal of Cancer · 23
PDF
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
2022 · Sara Elena Rebuzzi, Alessio Signori, et al. · Frontiers in Oncology · 21
PDF
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
2023 · Marco Stellato, Sebastiano Buti, et al. · International Journal of Molecular Sciences · 20
PDF
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study
2022 · Sara Elena Rebuzzi, Alessio Signori, et al. · Journal of Translational Medicine · 20
PDF
Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes
2018 · Alessia Cavo, Alessandra Rubagotti, et al. · Therapeutic Advances in Medical Oncology · 18
PDF
Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab
2023 · Martina Catalano, Sara Elena Rebuzzi, et al. · JAMA Network Open · 17
PDF
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists
2020 · Margaret Ottaviano, Marcello Curvietto, et al. · Journal for ImmunoTherapy of Cancer · 16
PDF
Treatment of elderly patients with metastatic renal cell carcinoma
2015 · Elisa Zanardi, Paolo Grassi, et al. · Expert Review of Anticancer Therapy · 11
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study
2024 · Martina Catalano, Sara Elena Rebuzzi, et al. · Frontiers in Immunology · 9
PDF
Genitourinary tumours in the targeted therapies era
2016 · Carlo Messina, Giulia Buzzatti, et al. · Anti-Cancer Drugs · 9
Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: technical aspects and primary staging setting
2025 · Matteo Bauckneht, Laura Evangelista, et al. · Clinical and Translational Imaging · 7
PDF
Antibody Response to COVID-19 mRNA Vaccines in Oncologic and Hematologic Patients Undergoing Chemotherapy
2022 · Manlio Mencoboni, Vincenzo Fontana, et al. · Current Oncology · 5
PDF
Baseline lymphocyte to monocyte ratio (LMR) and systemic inflammation index (SII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: Preliminary results of the Meet-URO 15 (I-BIO-REC) study.
2020 · Sara Elena Rebuzzi, Sebastiano Buti, et al. · Journal of Clinical Oncology · 5
Immunotherapy for genitourinary cancer
2016 · Carlo Cattrini, Chiara Dellepiane, et al. · Anti-Cancer Drugs · 5
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study
2024 · Veronica Murianni, Alessio Signori, et al. · Frontiers in Oncology · 4
PDF
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study
2023 · Sara Elena Rebuzzi, Matteo Brunelli, et al. · Cancers · 4
PDF
Baseline and early change of neutrophil to lymphocyte ratio (bNLR and ΔNLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: Preliminary results of the Meet-URO 15 (I-BIO-REC) study.
2020 · Sara Elena Rebuzzi, Sebastiano Buti, et al. · Journal of Clinical Oncology · 4
Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: PSA persistence, biochemical recurrence, hormone-sensitive and castration-resistant metastatic settings
2026 · Matteo Bauckneht, Laura Evangelista, et al. · Clinical and Translational Imaging · 3
PDF
Works count: 64
Citation count: 619
H-index: 14
I10-index: 15
Year
Topic
Type